Please wait while the formulary information is being retrieved.
VALSTAR (VALRUBICIN)
- Malignant tumor of urinary bladder
40 mg/mL intravesical solution
- Dosage information is not available
40 mg/mL intravesical solution
- Dosage information is not available
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- BCG vaccine, live (PF)
- flu vac,qval 2013-14 (2-49yrs)
- Flumist 2013-2014
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- Proquad (pf)
- Rotateq Vaccine
- rotavirus vaccine live, penta
- typhoid vaccine
- varicella virus vacc live (PF)
- Varivax (pf)
- Vivotif Berna Vaccine
- yellow fever vaccine live (PF)
- Yf-vax (pf)
- Zostavax (pf)
- zoster vaccine live (PF)
Contraindicated
- None
Severe
Moderate
- None
- Lactating mother
- Rupture of bladder
- Small capacity bladder
- Urinary tract infection
Contraindicated
- Bladder hyperactivity
- Bladder surgery
- Pregnancy
Severe
Moderate
- None
VALSTAR (VALRUBICIN)
- Malignant tumor of urinary bladder
- None
- Bladder irritability
- Dysuria
- Hematuria
- Increased urinary frequency
- Urinary incontinence
- Urinary tract infection
- Urine discoloration
More Frequent
Severe
Less Severe
- Chest pain
- Skin rash
- Vasodilation of blood vessels
- Abdominal pain with cramps
- Back pain
- Bladder pain
- Diarrhea
- Dizziness
- Fever
- Flatulence
- General weakness
- Headache disorder
- Malaise
- Nausea
- Nocturia
- Pelvic pain
- Urinary burning sensation
- Vomiting
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Hyperglycemia
- Peripheral edema
- Pneumonia
Less Severe
- Dysgeusia
- Myalgias
- Pruritus of skin
- Tenesmus
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
None
Valrubicin
- Severity Level:
D
- Additional Notes: Insuff human data; based on drug pharmacology dev tox may occur
Contraindicated
Valrubicin
Highly lipophilic; possible severe adverse effects.
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Highly lipophilic; possible severe adverse effects. |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Malignant tumor of urinary bladder | |
| C67 | Malignant neoplasm of bladder |
| C67.0 | Malignant neoplasm of trigone of bladder |
| C67.1 | Malignant neoplasm of dome of bladder |
| C67.2 | Malignant neoplasm of lateral wall of bladder |
| C67.3 | Malignant neoplasm of anterior wall of bladder |
| C67.4 | Malignant neoplasm of posterior wall of bladder |
| C67.5 | Malignant neoplasm of bladder neck |
| C67.6 | Malignant neoplasm of ureteric orifice |
| C67.7 | Malignant neoplasm of urachus |
| C67.8 | Malignant neoplasm of overlapping sites of bladder |
| C67.9 | Malignant neoplasm of bladder, unspecified |
| 0-9 | A-Z |
|---|---|
| C67 | Malignant neoplasm of bladder |
| C67.0 | Malignant neoplasm of trigone of bladder |
| C67.1 | Malignant neoplasm of dome of bladder |
| C67.2 | Malignant neoplasm of lateral wall of bladder |
| C67.3 | Malignant neoplasm of anterior wall of bladder |
| C67.4 | Malignant neoplasm of posterior wall of bladder |
| C67.5 | Malignant neoplasm of bladder neck |
| C67.6 | Malignant neoplasm of ureteric orifice |
| C67.7 | Malignant neoplasm of urachus |
| C67.8 | Malignant neoplasm of overlapping sites of bladder |
| C67.9 | Malignant neoplasm of bladder, unspecified |
Formulary Reference Tool